177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Phase 2

Not yet recruiting

• Conditions: Cytopenia; Thrombocytopenia; Metastatic Castration Resistant Prostate Cancer; Anemia
• Interventions: Drug: 177Lu-PSMA-617

• Registration Number: NCT07025512
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

The purpose of the study is to examine the clinical and biological effects of 177Lu-PSMA-617 in mCRPC patients with cytopenia\[s\].

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-06
• Study First Submitted: 2025-06-06
• Study First Submitted QC: 2025-06-09
• Study First Posted: 2025-06-17
• Last Update Submitted: 2025-07-22
• Last Update Posted: 2025-07-25
• Study Start: 2025-12-03
• Primary Completion: 2027-06-30
• Study Completion: 2029-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SingleArm	177Lu-PSMA-617	Treatment with 177Lu-PSMA-617

Primary Outcome Measures

Name	Time	Method
Safety and adverse events (AEs).	Through study completion; an average of 1 year	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Trial Locations

Locations (1)

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States